Literature DB >> 35016118

Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research.

Lauren V Moran1, Erica S Tsang2, Dost Ongur3, John Hsu4, May Y Choi5.   

Abstract

The 2017 National Inpatient Sample database was utilized to investigate the association between cannabis legalization in the United States and hospitalizations for psychosis associated with cannabis use. We compared the odds of hospital discharges for psychosis associated with cannabis use in adults between the Pacific census division (where most states legalized recreational cannabis use) and other divisions using multivariable logistic regression, adjusting for confounders. We calculated a score for each census division representing cannabis legality as the population-weighted sum of state scores: 1=illegal or cannabidiol/low potency cannabis; 2= medical marijuana; and 3=recreational and medical marijuana legalized. Pearson's correlation coefficients (r) quantified the relationship between scores and the proportion of hospitalizations with psychosis associated with cannabis. In 2017, there were an estimated 129,070 hospital discharges for psychosis associated with cannabis use. The Pacific census division had significantly higher odds of discharges than other divisions (adjusted odds ratio 1.55; 95% confidence interval 1.25 - 1.93). There was a significant correlation between the cannabis legality score and proportion of hospital discharges for psychosis associated with cannabis use (r = 0.67, p<0.05). In conclusion, we observed a higher proportion of hospital discharges for psychosis associated with cannabis use in areas with more liberal cannabis legalization laws.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabis; Legalization; Marijuana; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2022        PMID: 35016118      PMCID: PMC8833839          DOI: 10.1016/j.psychres.2022.114387

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  31 in total

1.  Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study.

Authors:  Daniel van Dijk; Maarten W J Koeter; Ron Hijman; René S Kahn; Wim van den Brink
Journal:  Schizophr Res       Date:  2012-02-06       Impact factor: 4.939

Review 2.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman
Journal:  J Clin Oncol       Date:  2017-07-31       Impact factor: 44.544

3.  Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.

Authors:  S Andréasson; P Allebeck; A Engström; U Rydberg
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

Review 4.  Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.

Authors:  Suzi B Claflin; Ingrid A F van der Mei; Bruce V Taylor
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08-02       Impact factor: 10.154

5.  Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys.

Authors:  Wilson M Compton; Beth Han; Christopher M Jones; Carlos Blanco; Arthur Hughes
Journal:  Lancet Psychiatry       Date:  2016-08-31       Impact factor: 27.083

6.  Public Health Effects of Medical Marijuana Legalization in Colorado.

Authors:  Jonathan M Davis; Bruce Mendelson; Jay J Berkes; Katie Suleta; Karen F Corsi; Robert E Booth
Journal:  Am J Prev Med       Date:  2015-09-16       Impact factor: 5.043

7.  Cannabis use and psychosis: a longitudinal population-based study.

Authors:  J van Os; M Bak; M Hanssen; R V Bijl; R de Graaf; H Verdoux
Journal:  Am J Epidemiol       Date:  2002-08-15       Impact factor: 4.897

8.  Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Authors:  John Peter Zajicek; Jeremy C Hobart; Anita Slade; David Barnes; Paul G Mattison
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-12       Impact factor: 10.154

Review 9.  Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.

Authors:  Arianna Marconi; Marta Di Forti; Cathryn M Lewis; Robin M Murray; Evangelos Vassos
Journal:  Schizophr Bull       Date:  2016-02-15       Impact factor: 9.306

10.  US Epidemiology of Cannabis Use and Associated Problems.

Authors:  Deborah S Hasin
Journal:  Neuropsychopharmacology       Date:  2017-08-30       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.